Amgen: Allowing Dividend Growth Investors To Capitalize On The Biotech Sell-Off

Home › Amgen: Allowing Dividend Growth Investors To Capitalize On The Biotech Sell-Off

In my opinion, Amgen is the only viable option for a conservative income investor looking for large-cap exposure to biotech.

05.11	Boeing strike ends as workers back 38% pay rise deal
05.11	Tropical Storm Rafael Public Advisory Number 6A
05.11	Summary for Tropical Storm Rafael (AT3/AL182024)
05.11	Tropical Storm Rafael Graphics
05.11	Atlantic Tropical Weather Outlook
05.11	Eastern North Pacific Tropical Weather Outlook
05.11	Tropical Storm Rafael Graphics
05.11	Tropical Storm Rafael Forecast Discussion Number 6
More »

je.st